Revance Therapeutics: The primary challenger with its long-lasting alternative, Daxxify. While smaller than AbbVie, they are ...

The FDA issued a complete response letter regarding AbbVie’s biologics license application for trenibotulinumtoxinE, a ...

AbbVie (NYSE: ABBV) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for ...

The regulator has sent a complete response letter (CRL) to AbbVie for trenibotulinumtoxinE (TrenibotE), a follow-up to its ...

The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective ...

The CDC reported that three individuals were hospitalized with botulism-type symptoms in May and June following self-injection of botulinum toxin they purchased online for cosmetic use. The case ...

Moderate to severe glabellar lines may be effectively and safely treated with YY001, a new recombinant botulinum toxin type A product.

AbbVie received a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) for ...

The results suggest that the dual-modality approach of combining oral doxycycline with intradermal BTX type A is far more ...

Botulism is a rare but potentially deadly illness caused by toxins from Clostridium bacteria. It can develop from ...